HighMark Wealth Management’s Ocular Therapeutix OCUL Stock Holding History

HighMark Wealth Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.36K	Hold	397	–	–	﹤0.01%	423
2025 Q4	$4.82K	Hold	397	–	–	﹤0.01%	411
2025 Q3	$4.64K	Hold	397	–	–	﹤0.01%	405
2025 Q2	$3.68K	Hold	397	–	–	﹤0.01%	433
2025 Q1	$2.91K	Hold	397	–	–	﹤0.01%	423
2024 Q4	$3.39K	Hold	397	–	–	﹤0.01%	409
2024 Q3	$3.45K	Hold	397	–	–	﹤0.01%	435
2024 Q2	$2.71K	Hold	397	–	–	﹤0.01%	444
2024 Q1	$3.61K	Hold	397	–	–	﹤0.01%	401
2023 Q4	$1.77K	Hold	397	–	–	﹤0.01%	477
2023 Q3	$1.25K	Hold	397	–	–	﹤0.01%	489
2023 Q2	$2.05K	Hold	397	–	–	﹤0.01%	458
2023 Q1	$2.09K	Hold	397	–	–	﹤0.01%	497
2022 Q4	$1.12K	Hold	397	–	–	﹤0.01%	466
2022 Q3	$2K	Hold	397	–	–	﹤0.01%	435
2022 Q2	$2K	Hold	397	–	–	﹤0.01%	440
2022 Q1	$2K	Hold	397	–	–	﹤0.01%	452
2021 Q4	$3K	Hold	397	–	–	﹤0.01%	411
2021 Q3	$4K	Hold	397	–	–	﹤0.01%	391
2021 Q2	$6K	Hold	397	–	–	﹤0.01%	334
2021 Q1	$7K	Hold	397	–	–	0.01%	301
2020 Q4	$8K	Sell	397 -2,000	-83%	-$29.7K	0.01%	271
2020 Q3	$18K	Hold	2,397	–	–	0.02%	177
2020 Q2	$20K	Hold	2,397	–	–	0.02%	135
2020 Q1	$11K	Hold	2,397	–	–	0.01%	146
2019 Q4	$9K	Buy	+2,397	New	+$8.33K	0.01%	230

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HighMark Wealth Management's OCUL Position: Q1 2026 in Review

HighMark Wealth Management held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 397 shares worth $3.36K. The position accounts for ﹤0.01% of the portfolio, ranked #423.

HighMark Wealth Management first reported a position in OCUL in Q4 2019 and has held it in 26 quarters since. The position peaked at $20K in Q2 2020. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

HighMark Wealth Management held 397 shares of Ocular Therapeutix worth $3.36K as of Q1 2026.
HighMark Wealth Management left its Ocular Therapeutix share count unchanged in Q1 2026.
Ocular Therapeutix made up ﹤0.01% of HighMark Wealth Management's portfolio in Q1 2026, its #423 holding.
HighMark Wealth Management first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 26 quarters since.
HighMark Wealth Management's Ocular Therapeutix position peaked at $20K in Q2 2020.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.